Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million - - BioPharm International

ADVERTISEMENT

Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million


Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI’s LifeSciences business unit for $185 million. ATMI LifeSciences specializes in single-use bioprocess systems and consumables for the bio/pharmaceutical industry. According to the press release, the transaction is expected to close in Pall’s fiscal third quarter and will be subject to closing conditions, regulatory approvals and labor-related notifications.

Pall announced that for the balance of fiscal 2014, the company expects the acquisition to add $20 $30 million in revenue, be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis. Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30–$3.50.

Source: Pall Corporation

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here